Is women’s health a niche, or one of the broadest investment themes in life science? At BioStock Life Science Summit 2026, Anesa Mulabecirovic Sahnoun, manager of DNB Fund Women’s Health, the world’s first actively managed equity fund dedicated entirely to the sector, made the case that the field is far wider than traditionally perceived.
In conversation with Cecilia Hallström, PhD, Mulabecirovic Sahnoun described how DNB builds its investment universe from the biology up, spanning pharmaceuticals, diagnostics and medtech across a woman’s lifespan. Women’s health today extends well beyond reproductive health, covering all diseases that affect women exclusively, differently or disproportionately. That breadth also strengthens the case for clinical development focused on women, so that the potential of new treatments can be evaluated correctly.
Mulabecirovic Sahnoun holds an MD, a PhD and an MBA, and draws on 15 years of experience from clinical practice and fund management.
See the full interview “Backing Women’s Health: A One-on-One with Anesa” below.
